Avalo Therapeutics (AVTX) Return on Equity (2016 - 2025)
Historic Return on Equity for Avalo Therapeutics (AVTX) over the last 11 years, with Q3 2025 value amounting to 1.02%.
- Avalo Therapeutics' Return on Equity rose 11100.0% to 1.02% in Q3 2025 from the same period last year, while for Sep 2025 it was 1.02%, marking a year-over-year increase of 11100.0%. This contributed to the annual value of 0.5% for FY2024, which is 179700.0% down from last year.
- As of Q3 2025, Avalo Therapeutics' Return on Equity stood at 1.02%, which was up 11100.0% from 0.41% recorded in Q2 2025.
- Avalo Therapeutics' Return on Equity's 5-year high stood at 2.74% during Q2 2023, with a 5-year trough of 6.05% in Q3 2023.
- In the last 5 years, Avalo Therapeutics' Return on Equity had a median value of 0.01% in 2021 and averaged 0.28%.
- Per our database at Business Quant, Avalo Therapeutics' Return on Equity plummeted by -60700bps in 2023 and then soared by 39200bps in 2024.
- Avalo Therapeutics' Return on Equity (Quarter) stood at 0.0% in 2021, then soared by 2086bps to 0.02% in 2022, then tumbled by -17701bps to 2.87% in 2023, then surged by 84bps to 0.46% in 2024, then crashed by -123bps to 1.02% in 2025.
- Its last three reported values are 1.02% in Q3 2025, 0.41% for Q2 2025, and 0.57% during Q1 2025.